𝔖 Bobbio Scriptorium

✦ LIBER ✦

PCN43 THE COST OF TREATING GRADE 3/4 ADVERSE EVENTS RELATED TO FIRST-LINE THERAPY WITH BEVACIZUMAB PLUS CHEMOTHERAPY VERSUS CETUXIMAB PLUS CISPLATIN/VINORELBINE FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN FRANCE

✍ Scribed by C Chouaid; A Vergnenegre; M Brunner; S Walzer

Book ID: 118611887
Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 81 KB
Volume: 12
Category: Article
ISSN: 1098-3015
DOI: 10.1016/s1098-3015(10)74294-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN44 TREATMENT COSTS OF GRADE 3/4 ADVER

PCN44 TREATMENT COSTS OF GRADE 3/4 ADVERSE EVENTS RELATED TO FIRST-LINE THERAPY WITH BEVACIZUMAB PLUS CHEMOTHERAPY VERSUS CETUXIMAB PLUS CISPLATIN/VINORELBINE FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN SPAIN

✍ J de Castro Carpeño; K Banz; AJ Castro 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB

PCN47 COSTS OF TREATING SEVERE ADVERSE E

PCN47 COSTS OF TREATING SEVERE ADVERSE EVENTS OBSERVED WITH A REGIMEN OF BEVACIZUMAB PLUS CHEMOTHERAPY VERSUS CETUXIMAB PLUS CISPLATIN/VINORELBINE IN THE FIRST-LINE THERAPY OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY

✍ HG Bischoff; D Heigener; K Banz; S Walzer 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB

PCN46 COST SAVINGS RELATED TO SUPERIOR A

PCN46 COST SAVINGS RELATED TO SUPERIOR ADVERSE EVENT PROFILE OF BEVACIZUMAB PLUS CHEMOTHERAPY VERSUS CETUXIMAB PLUS CISPLATIN/VINORELBINE IN THE FIRST-LINE THERAPY OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY: A SENSITIVITY ANALYSIS ON THE ECOG STATUS

✍ D Heigener; HG Bischoff; K Banz; S Walzer 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB

PCN89 A COST EFFECTIVENESS ANALYSIS DEMO

PCN89 A COST EFFECTIVENESS ANALYSIS DEMONSTRATES THE BENEFITS OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) VERSUS CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) IN SPAIN

✍ J de Castro Carpeño; A Castro Gómez; S Walzer 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB

PCN80 THE BENEFITS OF BEVACIZUMAB PLUS C

PCN80 THE BENEFITS OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) VERSUS CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) IN SWEDEN: RESULTS FROM A COST-EFFECTIVENESS ANALYSIS

✍ MJ Nuijten; C Holmberg; S Walzer 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB